Filed with ASX · · 10 pages · English
The report highlights the upcoming extension clinical study for SOF-SKN™, aimed at treating cutaneous lupus erythematosus, and advancements in its immuno-oncology program. Financially, the company reported cash reserves and net cash outflows from operating activities, while exploring options for securing additional capital. The report also mentions a recent capital raise and ongoing efforts to enhance its balance sheet through convertible note conversions.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
September 2026 Quarterly Activities Report and Appendix 4C • Lead clinical asset for the treatment of autoimmune skin diseases to progress to extension clinical study in patients with cutaneous lupus erythematosus • Clear progress and promising data from immuno-oncology program harnessing...
